In focus · trending topic

carbapenem-resistant Enterobac

1 stories · following the connections

Achaogen Announces Acceleration of Expected Timeline for Reporting Top-Line Results from Phase 3 EPIC Registration Clinical Trial of Plazomicin

By Nasdaq OMXApr 5, 2016, 12:00 PM UTC